P N Sambrook
ABSTRACT
The first choice for prevention of corticosteroid osteoporosis is a potent oral bisphosphonatefor example, alendronate or risedronate. Intravenous bisphosphonates should be considered for patients intolerant of the oral route. For patients receiving chronic low dose corticosteroids treatment with calcium and vitamin D may prevent further bone loss. Use of parathyroid hormone is promising.
Annals of the Rheumatic Diseases 2005;64:176-178
C/ San Pedro de Mezonzo nº 39-41
15701 – Santiago de Compostela
Teléfono: +34 986 417 374
Email: secretaria@sogacot.org
Coordinador del Portal y Responsable de Contenidos: Dr. Alejandro González- Carreró Sixto
